The Effects of the CF Carrier State on the Kidneys and Pancreas

Recruiting Observational Study
Carrier State Pancreatic Disease Kidney Diseases
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 100
Sex
Any
Study type
Observational
Participants needed
1,250 (estimated)
Sponsor
Philip Polgreen · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one vi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
CF Carrier Inclusion Criteria: * A CF Carrier identified via genetic testing Control Inclusion Criteria: * No previous CF carrier test results Exclusion Criteria: * CF patient status * Unable to speak English * Currently pregnant * Unable to provide written informed consent * Prisoner status * …
Contacts

Philip M Polgreen, MD

(319) 384-6194

philip-polgreen@uiowa.edu

CONTACT

Shelby L Francis, PhD

319-678-8037

shelby-francis@uiowa.edu

CONTACT